Investment Banking and Brokerage

NORDICUS PARTNERS CORP

NORDICUS PARTNERS CORP released FY2026 9 Months Earnings on February 13 (EST), actual revenue USD 0, actual EPS USD -0.2202

NORDICUS PARTNERS CORP released FY2026 Q3 earnings on February 13, 2026 (EST) with actual revenue of USD 0 and EPS of USD -0.0659

NORDICUS PARTNERS CORP released FY2026 Q2 earnings on November 14 EST, with actual revenue of USD 0 and EPS of USD -0.0845

NORDICUS PARTNERS CORP released FY2026 Semi-Annual earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1546

NORDICUS PARTNERS CORP released FY2026 Q1 earnings on August 20 (EST), actual revenue USD 0, actual EPS USD -0.0699

NORDICUS PARTNERS CORP released FY2025 Annual Earnings on July 29, 2025 (EST) with actual revenue of USD 5K and EPS of USD -0.32

NORDICUS PARTNERS CORP released FY2025 Q4 earnings on July 29 (EST) with actual revenue of USD 0 and EPS of USD -0.0355

Nordicus Partners Executives' Compensation Agreements Adjusted

Nordicus Partners Delays Filing 2025 Annual Report

Nordicus Partners Corporation Completes Private Placement of 54,000 Shares

NORDICUS PARTNERS CORP released FY2025 9 Months Earnings on April 2, 2025 (EST), with actual revenue of 5 K USD and EPS of -0.3156 USD

Nordicus Partners Corp released FY2025 Q3 earnings on April 2, 2025 (EST) with actual revenue of 2.5 K USD and EPS of -0.1322 USD

Orocidin A/S Announces Positive Results for Periodontitis Candidate Drug QR-01 in Preclinical Study

NORDICUS PARTNERS CORP released FY2025 H1 earnings on November 14 (EST), actual revenue 2.5 K USD, actual EPS -0.1873

NORDICUS PARTNERS CORP released FY2025 Q2 earnings on November 14 (EST), with actual revenue of 2.5 K USD and EPS of -0.1009

NORDICUS PARTNERS CORP released FY2025 Q1 earnings on August 19, 2024 (EST), with actual revenue of 0 and EPS of -0.0824

NORDICUS PARTNERS CORP released FY2024 earnings on July 3, 2024 (EST), with actual revenue of 2.5 K USD and EPS of -0.2881

NORDICUS PARTNERS CORP released FY2024 Q4 earnings on July 3, 2024 (EST), with actual revenue of 2.5 K USD and EPS of -0.0762

NORDICUS PARTNERS CORP released FY2023 Q4 earnings on July 3, 2024 (EST), with actual revenue of 0 and EPS of -3.7841

NORDICUS PARTNERS CORP released FY2024 Q3 earnings on February 6, 2024 (EST) with actual revenue of 0 USD and EPS of -0.067 USD

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

NORD

Nordic Semiconductor Completes NOK 131.5 Million Share Buyback Program

Tip Ranks

Nordic

Nordic Semiconductor Completes NOK 131.5 Million Share Buyback Program

Nordic Resources Files Interim Financial Report for December 2025 Half-Year

Nordic American Tanker Shipping

VanEck Oil Services ETF

SPDR O&G Equip

iShares US Oil Equip & Svcs

Nordic Resources Files Interim Financial Report for December 2025 Half-Year

SOXL

Nordic Semiconductor has announced the launch of its new nRF54LM20B System-on-Chip (SoC), enhancing its edge AI strategy with ultra-low-power capabilities. The integrated Neural Processing Unit (NPU) accelerates TensorFlow Lite models significantly, improving performance and energy efficiency for battery-powered devices. This innovation simplifies the development of edge AI applications, enabling real-time intelligence in wearables, smart home devices, and industrial sensors. The nRF54LM20 DK is now available, with volume production expected in Q2 2026. Nordic will showcase its advancements at Embedded World 2026 in Nuremberg.

fidelity

Direxion Semicon Bull 3X

Nordic Semiconductor strengthens nRF54L Series leadership in ultra-low-power edge AI

Nordic Semiconductor has expanded its nRF54L series with new low-cost Bluetooth LE system-on-chips (SoCs), the nRF54LS05A and nRF54LS05B. These SoCs are designed for simple applications like sensors and remote controls, offering robust Bluetooth LE connectivity and low power consumption. They feature an Arm Cortex M33 processor and are compatible with Nordic's nRF Connect SDK, facilitating efficient product development. The nRF54LS05A has 64 KB of RAM, while the nRF54LS05B has 96 KB. Both are available for evaluation, with production expected to start in Q3 2026.

prnewswire

05:16 ETNordic Semiconductor amplía la serie nRF54L con SoC Bluetooth LE de gama básica

Nordicus Partners Corp has released its Form 10-Q report for Q3, showing a revenue of $0, down from $2,500 last year. The company reported a loss from operations of $(1,122,172), an improvement from $(1,265,310) previously. Net loss decreased to $(1,247,524) from $(1,545,311), with a net loss per share of $(0.07). The company focuses on Nordic life sciences, managing three preclinical biotech firms. Future plans include advancing clinical trials and potential exits through sales or IPOs.

TradingView

Nordicus Partners Corp SEC 10-Q Report

Nordic shares rose on Monday, with the OMX Nordic 40 Index up 1.2%. Hoist Finance AB led gains, increasing 7.1%, followed by Verisure PLC at 7.0% and Elkem ASA at 6.2%. Sagax AB Series B saw the largest decline at 6.7%. In Denmark, the OMX Copenhagen 20 Index gained 2.0%, while the OMX Helsinki 25 Index rose 0.5%. Brent crude oil futures increased by 1.9%, and gold futures were up 2.4%. The WSJ Dollar Index fell 0.6%.

MorningStar

Nordic Shares Gain; Hoist Finance Tops Leaders

In Beverly Hills, California, on February 6, 2026, Nordicus Partners Corporation (OTCQB: NORD), a financial consulting firm focusing on aiding Nordic and U.S. life sciences companies in penetrating the U.S. market, shared a corporate update. This update included progress reports on its subsidiaries - Oricidin, Bio-Convert, and NoviThera, as well as details on the status of the Company's application to uplist on Nasdaq.

Unusual Whales

Nordicus Partners Corp (OTCQB: NORD) updates on subsidiaries Oricidin, Bio-Convert, NoviThera, and Nasdaq uplisting application.

Nordicus Partners Corporation (OTCQB: NORD) has provided a corporate update detailing developments in its subsidiaries, including Orocidin, Bio-Convert, and NoviThera, as well as the status of its Nasdaq uplisting application. Orocidin's pilot efficacy study is set to begin in Q3 2026, while Bio-Convert expects to complete its GMP product by August 2026. NoviThera is conducting a mouse study on psoriasis. The company is also exploring new acquisitions in the Nordic life sciences sector.

StockTitan

Nordicus Partners Corporation Corporate Update | NORD Stock News

NORDICUS PARTNERS CORP(NORD.US)

Nordic Semiconductor Completes NOK 131.5 Million Share Buyback Program

Nordic Resources Files Interim Financial Report for December 2025 Half-Year

Nordic Semiconductor strengthens nRF54L Series leadership in ultra-low-power edge AI

05:16 ETNordic Semiconductor amplía la serie nRF54L con SoC Bluetooth LE de gama básica

Nordicus Partners Corp SEC 10-Q Report

Nordic Shares Gain; Hoist Finance Tops Leaders

Nordicus Partners Corp (OTCQB: NORD) updates on subsidiaries Oricidin, Bio-Convert, NoviThera, and Nasdaq uplisting application.

Nordicus Partners Corporation Corporate Update | NORD Stock News